 The FDA has cleared BrainsWay Ltds NASDAQ:BWAY Deep Transcranial Magnetic Stimulation Deep TMS System to reduce comorbid anxiety symptoms in adult patients with depression, also known as anxious depression. BrainsWay submitted data from 573 patients in support of its application to the FDA. 